|
|
Volumn 335, Issue 6076, 2012, Pages 1554-
|
|
Biomarker tests need closer scrutiny, IOM concludes
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BIOLOGICAL MARKER;
DNA;
PROTEIN;
RNA;
BIOMARKER;
THEORETICAL STUDY;
BIOINFORMATICS;
CANCER PROGNOSIS;
CANCER THERAPY;
DIAGNOSTIC TEST;
FOOD AND DRUG ADMINISTRATION;
GENE ACTIVITY;
GENE EXPRESSION;
GENOMICS;
HUMAN;
MEDICAL ERROR;
METABOLITE;
NATIONAL HEALTH ORGANIZATION;
PRIORITY JOURNAL;
SHORT SURVEY;
TUMOR CELL;
CLINICAL TRIAL (TOPIC);
CONFLICT OF INTEREST;
GENE EXPRESSION PROFILING;
GENETICS;
MEDICAL RESEARCH;
MOLECULAR DIAGNOSIS;
NEOPLASM;
NOTE;
ORGANIZATION;
PERSONALIZED MEDICINE;
REPRODUCIBILITY;
STANDARD;
UNITED STATES;
ANTINEOPLASTIC AGENTS;
BIOMEDICAL RESEARCH;
CLINICAL TRIALS AS TOPIC;
CONFLICT OF INTEREST;
GENE EXPRESSION PROFILING;
HUMANS;
INDIVIDUALIZED MEDICINE;
INSTITUTE OF MEDICINE (U.S.);
MOLECULAR DIAGNOSTIC TECHNIQUES;
NEOPLASMS;
REPRODUCIBILITY OF RESULTS;
UNITED STATES;
|
|
EID: 84859150796
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.335.6076.1554 Document Type: Short Survey |
|
Times cited : (14)
|
|
References (0)
|
